Physicians at Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, will be among the first in the nation to administer a new cell-based immunotherapy to eligible patients with melanoma.
The School of Medicine has received a $7.8 million grant from the National Institutes of Health (NIH) to support a radiation oncology center that will aim to understand the biologic effects of radiation therapy in cancer treatment. Julie K. Schwarz, MD, PhD, and Clifford G. Robinson, MD, will lead the center.
Inconsistent Medicaid enrollment was found to be associated with higher risk of death in pediatric cancer patients, according to a new study from the Brown School.
According to a study led by researchers at the School of Medicine, diagnoses of breast cancer have increased steadily in women under age 50 over the past two decades. Studying such trends may offer clues to possible prevention strategies.
Washington University in St. Louis and Deerfield Management, a health-care investment firm, announced the launch of VeritaScience, a new private R&D collaboration designed to advance the discovery, clinical development and commercialization of promising therapeutic and diagnostic candidates with potential to benefit human health.
Matthew A. Ciorba, MD, a professor of medicine and director of the Inflammatory Bowel Disease Center at the School of Medicine, has received a $2.8 million award from the National Institutes of Health (NIH) to evaluate a new treatment for colorectal cancer.
Researchers and clinicians at Washington University in St. Louis developed a new imaging method to better diagnose lesions in the ovaries and fallopian tubes that may help to avoid unnecessary surgeries.
Robert Schreiber, of Washington University School of Medicine in St. Louis, is the 2024 Senior Scientist Winner of the Innovators in Science Award. The award recognizes his outstanding contributions to the field of cancer immunology.
A device aimed at enabling physicians to perform noninvasive blood-based biopsies in adults with brain tumors has received Food and Drug Administration “Breakthrough Device” designation. The device includes Washington University technology.
Scientists at the School of Medicine have analyzed the epigenomes of tumor cells across 11 cancer types and revealed important roles for this regulatory system of the genome in the way cancer forms, grows and spreads.